New generation dopaminergic agents 4. Exploiting the 2-methyl chroman scaffold. Synthesis and evaluation of two novel series of 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and indol-8-one derivatives
摘要:
The rational design, synthesis, and evaluation of two novel series of 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and indolone derivatives rue disclosed, based on the recently discovered D-2 agonist phenolic template prototype [i.e. the 7-OH-2-(aminomethyl)chroman nucleus]. The indolones were observed to have higher affinity and intrinsic activity than the corresponding indoles. (C) 1998 Elsevier Science Ltd. All rights reserved.
reaction of cotarnine and acyl/aryl ketones in green solvents provides an efficient approach to an array of privileged 1,2,3,4-tetrahydroisoquinolines in excellent yields by metal free Activaion of C(SP3)-H bonds. This one-pot procedure takes place under base-free conditions at room temperature, and tolerates a wide range of functionalities. The reaction is highly chemo-selective, scalable in multi-gram
The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.
本发明提供了作为AHR抑制剂有用的化合物,其组成物以及使用这些化合物的方法。
2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano-\x9b2,3-E!indol-8-ones and
申请人:American Home Products Corporation
公开号:US05750556A1
公开(公告)日:1998-05-12
Compounds of Formula I are selective autoreceptor agonists useful in treating disease states involving hyperactivity of dopamine systems: ##STR1## in which X is --(CH.sub.2).sub.n --; n is 1-3; R.sub.1 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl-methyl, bicyclo-alkylmethyl or --(CH.sub.2).sub.m YAr; where m is 0-4, Y is --CH.sub.2 --, and Ar is phenyl, halophenyl, alkylphenyl, dialkylphenyl or alkoxyphenyl; R.sub.2 is hydrogen or alkyl; R.sub.3 is hydrogen, halogen, alkyl, alkoxy or hydroxy; or a pharmaceutically acceptable salt thereof.
This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine.
This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.
This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine.
This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.